Figure 2From: Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging studyPrimary efficacy endpoint. Plot of adjusted mean change from baseline in trough FEV1 at Week 8 and summary of statistical analysis.Back to article page